Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 75,000 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 75,000 shares of the stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $22.53, for a total transaction of $1,689,750.00. Following the sale, the chief executive officer directly owned 1,654,597 shares of the company’s stock, valued at $37,278,070.41. This represents a 4.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Eric Venker also recently made the following trade(s):

• On Tuesday, December 23rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.45, for a total transaction of $4,490,000.00.
• On Tuesday, December 9th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.85, for a total transaction of $4,170,000.00.
• On Friday, November 7th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $20.22, for a total value of $4,044,000.00.
• On Friday, October 17th, Eric Venker sold 118,418 shares of Roivant Sciences stock. The shares were sold at an average price of $17.06, for a total value of $2,020,211.08.
• On Wednesday, October 15th, Eric Venker sold 414,683 shares of Roivant Sciences stock. The stock was sold at an average price of $16.93, for a total value of $7,020,583.19.
• On Thursday, October 16th, Eric Venker sold 318,282 shares of Roivant Sciences stock. The stock was sold at an average price of $17.05, for a total value of $5,426,708.10.
• On Monday, October 13th, Eric Venker sold 20,727 shares of Roivant Sciences stock. The shares were sold at an average price of $16.25, for a total value of $336,813.75.
• On Thursday, October 9th, Eric Venker sold 104,940 shares of Roivant Sciences stock. The shares were sold at an average price of $16.30, for a total value of $1,710,522.00.
• On Wednesday, October 8th, Eric Venker sold 138,602 shares of Roivant Sciences stock. The stock was sold at an average price of $16.20, for a total value of $2,245,352.40.
• On Monday, October 6th, Eric Venker sold 171,396 shares of Roivant Sciences stock. The stock was sold at an average price of $16.34, for a total transaction of $2,800,610.64.

Roivant Sciences Stock Down 2.4%

NASDAQ ROIV opened at $21.70 on Tuesday. The firm’s 50 day moving average is $20.65 and its 200-day moving average is $15.59. The company has a market capitalization of $15.09 billion, a PE ratio of -38.75 and a beta of 1.22. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $23.47.

Analyst Upgrades and Downgrades

ROIV has been the subject of a number of recent research reports. HC Wainwright increased their price objective on shares of Roivant Sciences from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Citigroup increased their price target on Roivant Sciences from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, November 11th. Bank of America raised their price target on Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a research note on Thursday, September 18th. The Goldman Sachs Group boosted their price target on Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Finally, Guggenheim reissued a “buy” rating and issued a $28.00 price objective on shares of Roivant Sciences in a report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $25.19.

Institutional Trading of Roivant Sciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Jones Financial Companies Lllp boosted its stake in shares of Roivant Sciences by 226.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after acquiring an additional 1,148 shares during the period. Allworth Financial LP boosted its position in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares during the period. Bessemer Group Inc. increased its holdings in shares of Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. CWM LLC raised its position in shares of Roivant Sciences by 44.6% in the second quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after purchasing an additional 920 shares during the period. Finally, Russell Investments Group Ltd. raised its position in shares of Roivant Sciences by 94.8% in the first quarter. Russell Investments Group Ltd. now owns 4,588 shares of the company’s stock valued at $46,000 after purchasing an additional 2,233 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.